Study
High-Dose Vitamin D3 May Improve Short-Term Survival in Older COVID-19 Patients
High-dose vitamin D3 reduced 14-day mortality in older adults with COVID-19, but benefits did not last beyond 28 days.
Summary
In plain language
In a recent study, researchers found that giving a high dose of vitamin D3 to older adults diagnosed with COVID-19 improved their chances of survival in the first 14 days. This trial included 254 participants aged 65 and older with COVID-19, who received either a high dose or a standard dose of vitamin D3 shortly after diagnosis. The high-dose group saw a significant reduction in deaths within two weeks. However, this benefit did not continue at 28 days. This finding suggests that high-dose vitamin D3 could be a helpful addition to early COVID-19 treatment for seniors, but further research is needed to understand long-term effects.
Details
Use the full description to understand the study design, methods, and the limits of the findings.
The study was a multicenter, randomized controlled trial conducted in France. Researchers compared high-dose (400,000 IU) vitamin D3 with standard-dose (50,000 IU) in older adults with COVID-19.
The high-dose vitamin D3 group had fewer deaths at 14 days compared to the standard-dose group, with 6% versus 11% mortality rates.
The study found no significant side effects from the high-dose vitamin D3.
The protective effect did not last beyond 28 days, highlighting the need for further investigation.
These findings may lead to discussions with healthcare providers about vitamin D3 as part of early COVID-19 care, particularly for seniors.
Full Study
Open the original publication for the complete methods, outcomes, and source material.
High-Dose Vitamin D3 May Improve Short-Term Survival in Older COVID-19 Patients
Published October 2026
Opens at the publisher · external site · may require institutional access
Research Quality Score
Scored October 22, 2026 using rubric mq-1.8_2026-07-06.
Assessment
The study's high score is due to its rigorous RCT design and publication in a high-quality journal. However, the open-label nature and potential conflicts of interest due to industry involvement reduced the bias control and conflicts scores. Statistical integrity was slightly reduced due to assumptions in power calculation. The study is highly relevant to the target population of older adults.
Category Breakdown
| Category | Score | Rating |
|---|---|---|
| Study design | 10.0/10 | |
| Bias control | 3.3/10 | |
| Statistical methods | 7.5/10 | |
| Reporting completeness | 10.0/10 | |
| Conflicts & funding | 5.0/10 | |
| Replication | 0.0/10 | |
| Relevance to chosen population | 10.0/10 | |
| Journal Reliability | 5.0/10 |
Additional Notes
This study investigated the effect of high-dose versus standard-dose vitamin D3 on 14-day mortality in older adults with COVID-19. It found that high-dose vitamin D3 reduced mortality at 14 days but not at 28 days, with no increase in adverse effects.
Assessed on the study's full text across 8 quality dimensions; conflict-of-interest disclosures were reviewed.
Conditions This Research Covers
These condition pages help connect the paper back to the real-world health concerns it addresses.
Treatments Evaluated in This Research
Review the interventions studied here and compare them against the broader treatment library.
Take the next step
Build a personalized plan using research-backed studies, conditions, and treatments.